Extracellular vesicles, including exosomes and microvesicles, are released by various cell types and can carry proteins, lipids, and genetic material. This cargo plays an essential role in mediating cell-to-cell communication and influencing the behavior of recipient cells, thus altering their physiological processes and contributing to tumor progression. In the case of multiple myeloma, the production of EVs by myeloma cells and their interaction with the bone marrow microenvironment are becoming focal points of study.

The bone marrow niche, composed of various cell types, including hematopoietic stem cells, osteoblasts, osteoclasts, and stromal cells, constitutes a vital reservoir for multiple myeloma cells. These interactions create a supportive environment for myeloma cell survival and proliferation. The communication facilitated through EVs poses a dual function, wherein they can promote survival signals within the tumor and simultaneously modulate the immune response, contributing to immune evasion.

Recent investigations have showcased how EVs derived from multiple myeloma cells can influence the behavior of bone marrow stromal cells. These stromal cells are critical in maintaining the supportive microenvironment for myeloma cells. By transferring bioactive molecules, such as cytokines and microRNAs, EVs drive changes in the gene expression profiles of stromal cells, enhancing their ability to support myeloma cell growth. This crosstalk not only nurtures the cancer cells but also leads to profound immunosuppressive effects, aiding the tumor’s ability to thrive in an otherwise hostile environment.

Moreover, the incorporation of EVs in the multiple myeloma–bone marrow niche interactions also reflects broader trends in the tumor-immune landscape. The cancer cells’ ability to shed such vesicles helps to reprogram immune cells in the bone marrow, promoting a non-inflammatory environment that favors tumor growth. For instance, EVs can carry molecules that inhibit T cell activation, preventing the anti-tumor immune response from becoming effective.

Importantly, the implications of these findings extend beyond basic science into clinical practice. The potential of targeting EV communication pathways offers a novel therapeutical avenue for multiple myeloma. By disrupting the EV-mediated interactions between myeloma cells and their microenvironment, new strategies could sensitize tumor cells to existing therapies, thus improving patient outcomes. Additionally, EVs hold potential as biomarkers for disease progression and treatment response, heralding the shift towards personalized medicine in oncology.

Characterizing the molecular composition of EVs from myeloma cells is another area garnering attention. Advancements in proteomic and genomic analyses have made it possible to identify specific markers and cargo associated with malignant behavior. By differentiating between the profiles of EVs derived from healthy and malignant cells, researchers aim to identify therapeutic targets and prognostic indicators, further enhancing the precision in treating multiple myeloma.

Notably, recent studies have uncovered specific microRNA signatures within the EVs that correlate with disease severity and response to therapies. These findings underscore the potential of EV-associated microRNAs as both prognostic tools and potential therapeutic agents. By harnessing these small RNA molecules, it may be possible to develop innovative therapeutic strategies that interfere with the signaling pathways responsible for tumor progression.

The timeline of these discoveries aligns with a greater understanding of the nuances involved in tumor biology, particularly how cancer cells exploit their environments for survival. With each new piece of the puzzle, researchers are slowly deciphering the crosstalk mechanisms that underpin multiple myeloma’s persistence and resilience against treatment.

In conclusion, the dialogue between multiple myeloma cells and their bone marrow microenvironment via extracellular vesicles unravels a complex tapestry of interactions critical for disease progression. As researchers continue to probe these interactions, the insights gained are poised to pave the way for novel interventions. The quest to decipher the role of EVs may not only aid in controlling myeloma but may also extend to broader applications across various malignancies, marking a significant stride in cancer research.

The clinical implications of these findings cannot be understated. As we begin to integrate the understanding of EVs into therapeutic practices, a paradigm shift towards more personalized and targeted approaches in multiple myeloma management is on the horizon. The future endeavors in research related to this topic will likely yield further revelations that could have vast implications for clinical practices.

Ultimately, the landscape of multiple myeloma treatment is set to evolve. With extracellular vesicles as pivotal players in the crosstalk of cancer and its microenvironment, numerous possibilities open up for innovative therapeutic strategies that could illuminate the path for patients battling this challenging malignancy.

As research in this area progresses, not only do we stand to gain a comprehensive understanding of multiple myeloma itself, but we may also uncover universal principles of cancer biology that could inform treatment approaches for various types of cancer. The continued exploration of extracellular vesicles and their signaling capabilities offers endless potential for advancing the frontiers of cancer treatment and patient care.

Subject of Research: The role of extracellular vesicles in the interaction between multiple myeloma and the bone marrow microenvironment.

Article Title: Extracellular vesicles in multiple myeloma-bone marrow niche crosstalk: from cellular dialogue to clinical perspectives.

Article References:

Forestiero, M., Zimbo, A.M., Gentile, G. et al. Extracellular vesicles in multiple myeloma-bone marrow niche crosstalk: from cellular dialogue to clinical perspectives. J Transl Med (2025). https://doi.org/10.1186/s12967-025-07445-8

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07445-8

Keywords: Extracellular vesicles, multiple myeloma, bone marrow microenvironment, crosstalk, tumor progression, immune evasion, therapeutic strategies, biomarkers.

CSCs share defining characteristics with normal stem cells, including the remarkable ability to self-renew, proliferate indefinitely, and differentiate into diverse tumor cell lineages. The preservation of these stem-like traits is essential for sustained tumor growth, metastasis, and resistance to therapies. Intriguingly, exosomal ncRNAs originating from various sources within the TME, notably the non-CSC tumor cells, have emerged as pivotal regulators that uphold CSC stemness by modulating the genetic and signaling landscape of these crucial cells. This modulation occurs through a targeted influence on genes and pathways intimately linked to stem cell maintenance, underscoring a complex regulatory circuitry that supports CSC vitality.

The role of exosomal ncRNAs in this context is multi-dimensional. Tumor-derived exosomes laden with ncRNAs have been documented to upregulate fundamental stemness markers, including CD44, CD133, OCT4, Sox2, and Nanog across a spectrum of cancers such as pancreatic, oral squamous cell carcinoma, colorectal, osteosarcoma, and nasopharyngeal carcinoma. This upregulation not only perpetuates the stem cell-like state of CSCs but also amplifies their invasive and metastatic potential, along with enhancing resistance to chemotherapeutic agents. Such findings signify that exosomal ncRNAs are critical drivers of aggressive tumor phenotypes and therapeutic recalcitrance via stemness augmentation.

Beyond tumor cells, mesenchymal stem cells (MSCs) residing within the TME exert a profound influence on CSC biology through their secretion of exosomes rich in ncRNAs. MSCs boast intrinsic high plasticity and an adaptive secretome responsive to environmental cues. Bone marrow-derived MSCs (BM-MSCs), for instance, release exosomal microRNAs like miR-155, which inhibit apoptosis and promote proliferation in multiple myeloma cells, concomitantly upregulating key stemness markers and drug resistance proteins. Similarly, BM-MSC-derived miR-142-3p has been shown to activate the Notch signaling pathway by modulating downstream targets such as CD133 and Lgr5, thereby bolstering CSC populations and their stem-like attributes in various cancers.

CAFs, an integral cellular component of the TME, further contribute to CSC stemness modulation via exosomal ncRNA transfer. Under hypoxic conditions, CAFs co-cultured with pancreatic cancer cells elevate the expression of stemness proteins including CD44, CD133, OCT4, and Sox2, leading to a marked increase in CSC populations and enhanced tumor resistance. Additional research has revealed that CAF-derived exosomes carrying circHIF1A act as molecular sponges for miR-580-5p within breast cancer cells, subsequently upregulating CD44 and cultivating stem-like traits that favor tumor progression. These findings shine a spotlight on the essential role of CAFs in remodeling CSC behavior through exosomal ncRNA-mediated communication.

Immune cells embedded in the TME also participate actively in shaping CSC stemness. M2 macrophage-derived exosomes, for example, are replete with miR-27a-3p, which targets thioredoxin-interacting protein (TXNIP) to promote liver CSC maintenance and activation. By manipulating immune signaling pathways, these exosomal ncRNAs facilitate CSC survival and proliferation, illustrating a nuanced mechanism through which immune components within the TME can indirectly sustain tumor aggressiveness.

At the molecular signaling level, exosome-mediated delivery of ncRNAs exerts a decisive influence on several stemness-related pathways crucial for CSC maintenance. The Wnt/β-catenin pathway is a prime example, serving as a linchpin in the self-renewal and undifferentiated state of CSCs. Studies in non-small cell lung cancer have identified long non-coding RNAs such as PKMYT1AR that interact with miR-485-5p to activate this canonical pathway, reinforcing stemness and facilitating tumor initiation. Concurrently, in lung adenocarcinoma, miR-1275 amplifies both Wnt/β-catenin and Notch signaling axes, jointly fostering a stem cell-like phenotype and promoting aggressive disease progression.

Notch signaling itself stands as a critical conduit in the regulation of CSC proliferation, maintenance, and resistance to chemotherapy. Research underscores that exosomal ncRNAs like miR-600 suppress KLF6 expression, resulting in increased Notch1 transcriptional activity which supports stemness and metastatic dissemination in ovarian cancer cells. Such modulation reveals a sophisticated mechanism by which CSCs exploit exosomal ncRNA cargo to fine-tune their self-renewal signaling programs and evade therapeutic pressure.

The PI3K/Akt pathway represents another signaling cascade modulated by exosomal ncRNAs that enhances CSC characteristics. Through intricate regulation of key downstream transcription factors, microRNAs regulate ovarian and endometrial CSC self-renewal and differentiation, maintaining malignant potential. Further complexity is introduced by CAF-secreted miR-146a-5p, which activates STAT3 and mTOR pathways in urothelial bladder cancer, augmenting CSC stemness and resistance to chemotherapeutic agents. Such multifaceted signaling modulation reinforces the central role of exosomal ncRNAs in driving oncogenic pathways that sustain CSCs.

Breast cancer models provide additional insights, where tumor-secreted exosomes enriched with miR-378a-3p and miR-378d target negative regulators such as Numb and DKK3. This targeting leads to activation of the EZH2/STAT3 axis, a pathway intimately tied to CSC maintenance and chemotherapy resistance. These findings demonstrate how ncRNAs can orchestrate a wide array of molecular programs to bolster tumor aggressiveness via continuous support of CSC populations.

Collectively, this body of research underscores the pivotal role of exosomal non-coding RNAs as critical molecular messengers that orchestrate the bidirectional communication between non-CSCs and CSCs. Through the modulation of gene expression and activation of multiple converging signaling pathways, these ncRNAs sustain the stemness phenotype critical for tumor persistence and progression. Therapeutic strategies aimed at targeting these exosomal ncRNAs or their downstream pathways hold tremendous promise for disrupting CSC-driven tumor resilience and improving clinical outcomes.

Advancing this field demands a deeper mechanistic understanding of exosomal ncRNA biogenesis, cargo selection, and cellular uptake dynamics within the TME. Moreover, the heterogeneity of exosomal populations and their context-specific effects highlight the necessity for precision medicine approaches aimed at selectively modulating harmful exosomal signaling without disrupting physiological communication. As research continues to unravel these complex networks, new biomarkers and therapeutic targets for combating cancer stemness and therapy resistance are poised to emerge.

In conclusion, the evolving landscape of cancer research places exosomal non-coding RNAs at the forefront of our understanding of tumor biology. Their ability to mediate intercellular crosstalk between diverse cellular constituents of the tumor microenvironment and regulate the fundamental stemness characteristics of cancer stem cells offers a paradigm-shifting perspective. Harnessing this knowledge could pave the way for innovative diagnostic and treatment modalities that specifically dismantle the molecular foundations of cancer persistence and aggressiveness.

Subject of Research:
Exosomal non-coding RNAs as regulators of cancer stem cell stemness within the tumor microenvironment.

Article Title:
Exosomal non-coding RNAs: mediators of crosstalk between cancer and cancer stem cells.

Article References:
Wang, S., Shu, J., Wang, N. et al. Exosomal non-coding RNAs: mediators of crosstalk between cancer and cancer stem cells. Cell Death Discov. 11, 434 (2025). https://doi.org/10.1038/s41420-025-02726-z

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-025-02726-z